<DOC>
	<DOCNO>NCT02085148</DOCNO>
	<brief_summary>The aim study determine dose regorafenib safe child adolescent also investigate pharmacokinetics ( explores body drug ) regorafenib ( study drug ) child adolescent . Additional objective study : - To assess tolerability regorafenib child adolescents - To assess whether tumor response regorafenib - To assess palatability acceptability regorafenib tablet child</brief_summary>
	<brief_title>A Phase I Dose Finding Study Children With Solid Tumors Recurrent Refractory Standard Therapy</brief_title>
	<detailed_description />
	<criteria>Age : 6 month le 18 year old Diagnosis : subject must histologic verification solid malignancy original diagnosis . Subjects recurrent refractory solid tumor eligible , include primary CNS tumor subject know CNS metastases Subject 's current disease state must one know effective therapy therapy proven prolong survival acceptable quality life . Effective therapy may include surgery , radiation therapy , chemotherapy combination modality . Subjects must least one measurable evaluable lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) , version 1.1 . For neuroblastoma subject osteomedullary disease , SIOPEN ( International Society Pediatric Oncology Europe Neuroblastoma Group ) score use . Bone scan ( clinically indicate ) obtain ≤ 12 week prior start treatment . Life expectancy least 12 week time sign informed consent/assent Performance level : Karnofsky ≥ 70 % subject &gt; 12 year age Lansky ≥ 70 % subject ≤ 12 year age . Note performance level consider reduced limitation movement play cause motor paresis paralysis due disease . Any neurological deficit subject must stable minimum 1 week prior first dose study treatment . Adequate renal , hepatic hematologic function Prior treatment regorafenib . Subjects permanently withdraw study participation allow reenter study . Other anticancer treatment , include investigational new drug within 28 day 5 drug halflives ( drug halflife subject know ) , whichever short ( within 6 week mitomycin C ) , start study treatment Subjects uncontrolled baseline hypertension high Grade 1 NCICTCAE v.4.0 ( recurrent persistent [ ≥24 hour ] blood pressure [ BP ] &gt; ULN : BP &gt; 95th percentile age , height , gender measure ) Unresolved toxicity high NCICTCAE v. 4.0 Grade 1 attribute prior therapy/procedure ( exclude alopecia , chemotherapyinduced ototoxicity , Grade 2 chemotherapyinduced neuropathy , per eligibility criterion , anemia hemoglobin ≥ 8 mg/dL ANC ≥ 1.0 x 10 9/L ) . Any malignant disease treat prior study</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pediatric cancer</keyword>
</DOC>